TScan Therapeutics (NASDAQ:TCRX) Major Shareholder Lynx1 Capital Management Lp Acquires 75,500 Shares

TScan Therapeutics, Inc. (NASDAQ:TCRX) major shareholder Lynx1 Capital Management Lp purchased 75,500 shares of the business’s stock in a transaction dated Monday, December 22nd. The shares were bought at an average price of $0.90 per share, with a total value of $67,950.00. Following the purchase, the insider directly owned 8,012,916 shares of the company’s stock, valued at approximately $7,211,624.40. The trade was a 0.95% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Lynx1 Capital Management Lp also recently made the following trade(s):

• On Tuesday, December 23rd, Lynx1 Capital Management Lp acquired 6,232 shares of TScan Therapeutics stock. The stock was purchased at an average price of $0.90 per share, for a total transaction of $5,608.80.
• On Friday, December 19th, Lynx1 Capital Management Lp acquired 80,069 shares of TScan Therapeutics stock. The stock was purchased at an average cost of $0.90 per share, for a total transaction of $72,062.10.

TScan Therapeutics Stock Performance

Shares of TCRX stock traded up $0.01 during mid-day trading on Tuesday, hitting $0.91. The stock had a trading volume of 342,212 shares, compared to its average volume of 538,535. The firm has a market cap of $51.68 million, a PE ratio of -0.81 and a beta of 1.04. The company’s 50-day simple moving average is $1.37 and its 200-day simple moving average is $1.63. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.44 and a quick ratio of 6.44. TScan Therapeutics, Inc. has a fifty-two week low of $0.88 and a fifty-two week high of $3.43.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.07. The firm had revenue of $2.51 million during the quarter, compared to the consensus estimate of $1.98 million. TScan Therapeutics had a negative net margin of 1,692.96% and a negative return on equity of 73.33%. Sell-side analysts anticipate that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on TCRX. HC Wainwright decreased their price objective on shares of TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Thursday, November 13th. Morgan Stanley downgraded shares of TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research report on Friday, November 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Wednesday, October 8th. Needham & Company LLC dropped their price objective on TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, November 4th. Finally, BTIG Research cut TScan Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, November 4th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $6.60.

Hedge Funds Weigh In On TScan Therapeutics

Hedge funds have recently bought and sold shares of the stock. Deutsche Bank AG raised its holdings in shares of TScan Therapeutics by 149.4% in the first quarter. Deutsche Bank AG now owns 52,559 shares of the company’s stock worth $73,000 after acquiring an additional 31,481 shares during the last quarter. Nuveen LLC acquired a new position in TScan Therapeutics in the 1st quarter valued at about $97,000. Hsbc Holdings PLC purchased a new position in TScan Therapeutics in the 1st quarter valued at about $49,000. Troluce Capital Advisors LLC boosted its stake in shares of TScan Therapeutics by 58.3% during the 1st quarter. Troluce Capital Advisors LLC now owns 83,758 shares of the company’s stock worth $116,000 after purchasing an additional 30,844 shares during the last quarter. Finally, BVF Inc. IL grew its holdings in shares of TScan Therapeutics by 63.6% during the first quarter. BVF Inc. IL now owns 4,889,474 shares of the company’s stock worth $6,747,000 after buying an additional 1,900,000 shares in the last quarter. Hedge funds and other institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.